Shares of drug maker AcelRx Pharmaceuticals (NASDAQ:ACRX) slumped on Thursday, falling 13% as of 10:34 a.m.
Analysts are cautious to sure-fire confident on mover and shakers sending the Street into a frenzy today.
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) saw its shares crater by as much as 62% today on exceptionally high volume. This drop was triggered by …
A heavy-hitter catalyst is about to go up to bat for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) with a key FDA decision looming in the foreground, …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are getting enthusiastic again after the biotech firm’s Phase 3 IAP312 clinical trial of Zalviso, approved in the …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are quaking today in the upshot of earnings not so far off the mark from second quarter expectations. …
The next key catalyst for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Dsuvia’s Prescription Drug User Fee Act (PDUFA) on October 12, 2017 for the …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) reported key results from the Phase 3 IAP312 study of ZALVISO® (sufentanil sublingual tablet system), an investigational product candidate …
Will the FDA grant its key blessing to AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) come October 12th for its lead acute pain reliever drug candidate, …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced the appointment of Raffi Asadorian as chief financial officer, effective August 16, 2017. Mr.
